• The Objectives/Methods/Results/Conclusions sections are limited to 400 words total.
• Authors are not restricted by the number of abstracts and/or videos submitted. However, no more than 15 authors per submission are allowed. Ensure all authors are included at the time of submission. You will not be able to add an author after the portal closes or acceptance.
• Abstract submissions must be entered in the English language.
• Updates and edits to submissions can be made as needed prior to the submission deadline.
• Titles and abstract content may not include author, institutional and/or proprietary names.
• Graphics
  • No more than two images may be uploaded. Multiple panel figures are not allowed (i.e., a single figure with parts 1A, 1B, 1C).
  • Images must be the original, unpublished property of the author(s). Written permission must be obtained from the rights-holder to reuse any copyrighted material.
  • Resolution should be 300 DPI at 3” wide or larger.
• SA-CME Question Writing Requirements
  • One question; multiple-choice format.
  • A stem, typically clinical in nature (but non-clinical stems), may be used when appropriate to test the particular content area.
  • One correct answer and four incorrect distracters (for a total of FIVE possible answers).

You must identify the following roles during the submission process

Download the Full Submission Policies and Guidelines

To ensure a fair and unbiased review process, please refrain from including any identifying information in your submission. This includes, but is not limited to:

• Author names, affiliations, or contact information.
• Acknowledgments that reference specific individuals, institutions, or grants.
• References to your previous work that could reveal your identity (use "Author" or "this work" in place of self-citations).

Submissions that include identifying information may be returned for revisions or disqualified from the review process.

Do not use proprietary drug names in your abstract body or title; use generic names instead (e.g., "Herceptin” should be written as "trastuzumab"). If the proprietary name is the only one used for the particular drug or product to which you are referring (e.g., HercepTest or CyberKnife), you may use that name; however, do not include a trademark or registration symbol.

The work represented in the abstract must NOT have been presented nor published at any scientific meeting or journal prior to that year’s Vascular Annual Meeting. Failure to comply with the above rules will result in the abstract being rejected or later withdrawn. In addition, the penalty may include a one-year ban from presentation at the Vascular Annual Meeting, subject to the discretion of the Program Committee.

It is the responsibility of the submitting author or sponsoring SVS member to consult with the Program Committee prior to submission if there is any question regarding possible redundancy of the work to be presented. Direct inquiries to vameducation@vascularsociety.org.